Better Than Statins? The Truth About the New Cholesterol Drug

For the references and more information on other medications, supplements, and what I’m doing, see the newsletter: https://staycuriousmetabolism.substack.com/p/the-big-new-pcsk9-studyand-what-everyones?r=40ekz2 Lp(a) Explainer Video: https://youtu.be/iVwDJqJiTEY Lp(a) and Vitamin C, Video: https://youtu.be/3rbJnKnhg3s Lp(a) and Waist-to-Hip ratio, Letter: https://staycuriousmetabolism.substack.com/p/why-lpa-may-not-be-as-dangerous-as?r=40ekz2 Statins Damage Mitochondria, Video: https://youtu.be/qHXMI3DudEc Statins Slash GLP-1, Video: https://youtu.be/6NomrgjK1yQ Heart Map! https://heartmap.staycuriousmetabolism.com A massive new cardiology study just hit the New England Journal of Medicine — and headlines everywhere claimed that PCSK9 inhibitors like Repatha can reduce heart attack and stroke risk by 25%, even in people who have never had an event before. It sounds like a revolution. It sounds like a breakthrough. But the real story has more nuances. In this video, we dig into what PCSK9 inhibitors truly do, why LDL and ApoB drop so dramatically and how these drugs compare to statins — including the downsides that rarely make it into mainstream coverage, like increased diabetes risk, mitochondrial damage. We’ll also explore a new emerging compound — a cyclic peptide PCSK9 inhibitor but can be taken by mouth instead of by injection — and I’ll share the experiment I’m running on myself. Chapters 0:00 – A Breakthrough in Cardiology! Maybe? 1:33 – I Promise You: A Balanced Assessment of Latest Findings 2:20 – New Randomized Controlled Trial in the New England Journal of Medicine 3:06 – Mechanism: How PCSK9 inhibitors work 4:05 – Primary Prevention vs Secondary Prevention 6:05 – The Results: 25% Risk Reduction. 1.8% Absolute Reduction 8:11 – Beyond the Headlines: A Balanced Summary 8:55 – PCSK9 vs Statins: Pros and Cons 10:54 – Other Medications and Supplements 11:30 – Let’s Summarize One Big Point #pcsk9 #statins #cholesterol #apoB #LDL #heartdisease #cardiology #metabolichealth #NEJM #medicalstudyexplained #cardiovascularprevention #lipidlowering #repatha #evolocumab #lpa #GLP1 #insulinresistance #longevityscience #healthscience #NickNorwitz #StayCuriousMetabolism #scienceexplainer #heartattackprevention #strokerisk #statinssideeffects #evidencebasedmedicine #staycurious